Compare · NITO vs NTR
NITO vs NTR
Side-by-side comparison of N2OFF Inc. (NITO) and Nutrien Ltd. (NTR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NITO and NTR operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- NTR carries a market cap of $32.82B.
- Over the past year, NITO is down 86.5% and NTR is up 14.3% - NTR leads by 100.8 points.
- NTR has hit the wire 3 times in the past 4 weeks while NITO has been quiet.
- NTR has more recent analyst coverage (25 ratings vs 0 for NITO).
PerformanceNITO-86.45%NTR+8.71%
2025-07-28+0.00%2026-02-25
- Company
- N2OFF Inc.
- Nutrien Ltd.
- Price
- $1.25+32.98%
- $68.13-0.58%
- Market cap
- -
- $32.82B
- 1M return
- -15.54%
- +12.86%
- 1Y return
- -86.45%
- +14.31%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 0
- 3
- Recent ratings
- 0
- 25
NTR
Nutrien Ltd.
Nutrien Ltd. provides crop inputs, services, and solutions. The company offers potash, nitrogen, phosphate, and sulfate products; and financial solutions. It also distributes crop nutrients, crop protection products, seeds, and merchandise products through approximately 2,000 retail locations in the United States, Canada, South America, and Australia. The company was incorporated in 2017 and is headquartered in Saskatoon, Canada.
Latest NITO
- SEC Form PRE 14A filed by N2OFF Inc.
- N2OFF Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
- N2OFF Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure
- N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company
- MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases
- Chief Executive Officer Palach David was granted 100,000 units of Restricted Shares of Common Stock (SEC Form 4)
- Controller Zakai Shlomo was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)
- Director Weiss Amitay was granted 116,286 units of Restricted Shares of Common Stock (SEC Form 4)
- Chief Financial Officer Barda Lital was granted 50,000 units of Restricted Shares of Common Stock (SEC Form 4)
- In Spaceflight Conditions: N2OFF's MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions
Latest NTR
- Nutrien Announces Release Dates for Second Quarter 2026 Results and Conference Call
- Nutrien downgraded by Jefferies with a new price target
- SEC Form 6-K filed by Nutrien Ltd.
- Nutrien upgraded by Scotiabank with a new price target
- SEC Form 11-K filed by Nutrien Ltd.
- SEC Form 11-K filed by Nutrien Ltd.
- SEC Form 11-K filed by Nutrien Ltd.
- Nutrien Cautions Investors Regarding Ocehan LLC's Below Market "Mini-Tender" Offer
- Nutrien downgraded by Berenberg with a new price target
- SEC Form 6-K filed by Nutrien Ltd.